Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Laird Superfood, Inc.LSF · Entity 137 | Director | July 09, 2026 | July 13, 2026 |
| Niagen Bioscience, Inc.NAGE · Entity 6146 | Director | June 24, 2026 | June 26, 2026 |
| Super League Enterprise, Inc.SLE · Entity 6409 | Director | December 31, 2025 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Laird Superfood, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-07-09 | Direct | 60,000 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-07-09 | Direct | 25,000 |
Reported balance
After 2026-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-09 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2036-07-09 | Direct | 25,000 |
Reported balance
After 2026-07-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-09 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date.
Niagen Bioscience, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2036-06-23 | Direct | 31,746 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 31,746 · Balance 31,746 F1: Option vests 100% on June 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests 100% on June 24, 2027.
Super League Enterprise, Inc.
Report date December 31, 2025 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,477 |
Last balance in matching sequence
After 2025-10-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-10-01 · Grant · Acquired 962 · Balance 1,031 F1: Represents grant of restricted stock units ("RSUs"). The RSUs vested in full on the date of the Issuer's annual meeting of stockholders held on October 20, 2025. F2: On January 23, 2026, the Issuer effectuated a 1-for-12 reverse split ("Reverse Split") of the Issuer's common stock. This Form 5 reports holdings as of December 31, 2025, with all share amounts reported herein adjusted for the Reverse Split. Row 2 · 2025-10-20 · Grant · Acquired 1,446 · Balance 2,477 F3: Represents grant of RSUs. The RSUs will vest in full on the date of the Issuer's 2026 annual meeting of stockholders. F2: On January 23, 2026, the Issuer effectuated a 1-for-12 reverse split ("Reverse Split") of the Issuer's common stock. This Form 5 reports holdings as of December 31, 2025, with all share amounts reported herein adjusted for the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units ("RSUs"). The RSUs vested in full on the date of the Issuer's annual meeting of stockholders held on October 20, 2025.
F2: On January 23, 2026, the Issuer effectuated a 1-for-12 reverse split ("Reverse Split") of the Issuer's common stock. This Form 5 reports holdings as of December 31, 2025, with all share amounts reported herein adjusted for the Reverse Split.
F3: Represents grant of RSUs. The RSUs will vest in full on the date of the Issuer's 2026 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 23:55 UTC | Laird Superfood, Inc. LSF · Entity 137 | GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023470 · rdgdoc.xml · derivative · entry 3 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Laird Superfood, Inc. Common Stock · 25,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 23:55 UTC | Laird Superfood, Inc. LSF · Entity 137 | GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023470 · rdgdoc.xml · derivative · entry 2 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Laird Superfood, Inc. Common Stock · 25,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 23:55 UTC | Laird Superfood, Inc. LSF · Entity 137 | GrantOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001437749-26-023470 · rdgdoc.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Laird Superfood, Inc. Common Stock · 60,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: The stock options vest as to 25% of the shares on each of the first four anniversaries of the grant date. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:57 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 31,746 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001769529-26-000003 · wk-form4_1782511043.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,746 Underlying: Common Stock · 31,746 shares Expires 2036-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2027. Read SEC document |
| October 20, 2025 Filed Mar 3, 2026 14:06 UTC | Super League Enterprise, Inc. SLE · Entity 6409 | GrantCommon Stock | 1,446 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001769529-26-000002 · form5-03032026_020316.xml · nonDerivative · entry 2 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,477 F3 · shares: Represents grant of RSUs. The RSUs will vest in full on the date of the Issuer's 2026 annual meeting of stockholders. F3 · price: Represents grant of RSUs. The RSUs will vest in full on the date of the Issuer's 2026 annual meeting of stockholders. F2 · balance_after: On January 23, 2026, the Issuer effectuated a 1-for-12 reverse split ("Reverse Split") of the Issuer's common stock. This Form 5 reports holdings as of December 31, 2025, with all share amounts reported herein adjusted for the Reverse Split. Read SEC document |
| October 01, 2025 Filed Mar 3, 2026 14:06 UTC | Super League Enterprise, Inc. SLE · Entity 6409 | GrantCommon Stock | 962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001769529-26-000002 · form5-03032026_020316.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,031 F1 · shares: Represents grant of restricted stock units ("RSUs"). The RSUs vested in full on the date of the Issuer's annual meeting of stockholders held on October 20, 2025. F1 · price: Represents grant of restricted stock units ("RSUs"). The RSUs vested in full on the date of the Issuer's annual meeting of stockholders held on October 20, 2025. F2 · balance_after: On January 23, 2026, the Issuer effectuated a 1-for-12 reverse split ("Reverse Split") of the Issuer's common stock. This Form 5 reports holdings as of December 31, 2025, with all share amounts reported herein adjusted for the Reverse Split. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:29 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001628280-25-033148 · wk-form4_1750973339.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2026. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001628280-24-038470 · wk-form4_1724713582.xml · derivative · entry 5 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001628280-24-038470 · wk-form4_1724713582.xml · derivative · entry 4 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 3,000 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 23,000 | $3.57 | $82,110.00 |
DisclosureSEC source: 0001628280-24-038470 · wk-form4_1724713582.xml · nonDerivative · entry 3 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The weighted average sale price for the transaction reported was $3.57, and the range of prices were between $3.52 and $3.64. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 20,000 | $1.67 | $33,400.00 |
DisclosureSEC source: 0001628280-24-038470 · wk-form4_1724713582.xml · nonDerivative · entry 2 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 3,000 | $1.64 | $4,920.00 |
DisclosureSEC source: 0001628280-24-038470 · wk-form4_1724713582.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:44 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001628280-24-029652 · wk-form4_1719265458.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Option vests 100% on June 20, 2025. Read SEC document |
| September 07, 2023 Filed Apr 29, 2024 23:16 UTC | Super League Enterprise, Inc. SLE · Entity 6409 | GrantCommon Stock | 27,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-011710 · form4-04292024_110435.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,740 F1 · price: Represents grant of restricted stock units ("RSUs") issued in connection with the Reporting Person's service on the Issuer's Board of Directors. The RSUs will vest in full on the date of the Issuer's 2024 annual shareholders meeting. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:26 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001628280-23-022533 · wk-form4_1686950795.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Option vests 100% on June 15, 2024. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:23 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001628280-22-017715 · wf-form4_165585019790330.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Option vests 100% on June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 10:00 UTC | Super League Enterprise, Inc. SLGG · Entity 6409 | GrantCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-006795 · form4-06212022_060636.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,273 F1 · shares: Represents grant of restricted stock units ("RSUs") issued in connection with the Reporting Person's service on the Issuer's Board of Directors. The RSUs will vest in full on the date of the Issuer's 2023 annual shareholders meeting. F1 · price: Represents grant of restricted stock units ("RSUs") issued in connection with the Reporting Person's service on the Issuer's Board of Directors. The RSUs will vest in full on the date of the Issuer's 2023 annual shareholders meeting. Read SEC document |
| April 15, 2022 Filed Apr 20, 2022 00:27 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001628280-22-009591 · wf-form4_165041444722067.xml · derivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-04-14 F1 · derivative.exercise_date: The option vests in three substantially equal annual installments beginning on April 15, 2023. Read SEC document |
| May 27, 2021 Filed Jun 2, 2021 19:42 UTC | Super League Enterprise, Inc. SLGG · Entity 6409 | GrantCommon Stock | 12,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002759 · form4-06022021_120609.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,273 F1 · price: Represents grant of restricted stock units ("RSUs") issued in connection with the Reporting Person's service on the Issuer's Board of Directors. The RSUs will vest in full on the date of the Issuer's 2022 annual shareholders meeting. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 14:48 UTC | Super League Enterprise, Inc. SLGG · Entity 6409 | GrantCommon Stock | 36,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-20-002003 · form4-08042020_070822.xml · nonDerivative · entry 1 Patrick Kristin · CIK 0001769529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,799 F1 · price: Represents grant of restricted stock units ("RSUs") issued in connection with the Reporting Person's service on the Issuer's Board of Directors. The RSUs will vest in full on the date of the Issuer's 2021 annual shareholders meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.